In a report released today, Kumaraguru Raja from Brookline Capital Markets reiterated a Buy rating on Vaxart (VXRT – Research Report), with a price target of $10.00. The company's shares closed last Thursday at $3.57, close to its 52-week low of $2.49. According to TipRanks.com, Raja is a 2-star analyst with an average return of 1.0% and a 34.4% success rate. Raja covers the Healthcare sector, focusing on stocks such as Cyclacel Pharmaceuticals, Oncternal Therapeutics, and Caladrius Biosciences. Currently, the analyst consensus on Vaxart is a Moderate Buy with an average price target of $8.00.
https://www.tipranks.com/news/blurbs/brookline-capital-markets-thinks-vaxarts-stock-is-going-to-recover-2?utm_source=advfn.com&utm_medium=referral
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Dec 2022 to Jan 2023 Click Here for more Vaxart Charts.
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Jan 2022 to Jan 2023 Click Here for more Vaxart Charts.